“Three antibodies” intervention treatment and follow-up for hepatitis B liver failure survivors
MO Shizao1 WANG Zhenchang2 LYU Yanhang3 WU Shanshan3 WEI Qinying2 PENG Li′na1
1.Department of Hepatology, Teng County Hospital of Traditional Chinese Medicine, Wuzhou City, Guangxi Zhuang Autonomous Region, Wuzhou 543300, China; 2.Department of Spleen and Stomach Liver Diseases, Guangxi International Zhuang Medical Hospital Affiliated to Guangxi University of Traditional Chinese Medicine Guangxi Zhuang Autonomous Region, Nanning 530020, China;
3.Craduate school, Guangxi University of Chinese Medicine, Guangxi Zhuang Autonomous Region, Nanning 530000, China
Abstract：Objective To observe the curative effect of anti-virus, anti-inflammation and anti-fibrosis (“three antibodies”) on the survivors of hepatitis B liver failure. Methods From January 2016 to January 2018, 240 cases of hepatitis B liver failure survivors were confirmed in the Department of Spleen and Stomach Liver disease of Guangxi International Zhuang Medical Hospital, liver Disease Center of the First Affiliated Hospital of Guangxi University of Chinese Medicine, and the Teng County Hospital of Traditional Chinese Medicine, Wuzhou City, Accordance with 1:1:2 principle, they were divided into group A (simple antivirus, n = 60), group B (antivirus combined with compound Yiganling Capsules, n = 60), and group C (“ three anti-virus ”combined treatment, namely antivirus combined with compound Yiganling Capsules and Liangan Chemical fiber granule, n = 120) by random number table method. The biochemical responses, hepatic fibrosis indexes, HBeAg, HBeAb, HBeAg/Ab conversion rates and liver tissue score of the three groups before and after treatment were analyzed. Results After 12 and 24 months of treatment, the biochemical response index cereal third transaminase (ALT), total bilirubin (TBil) and albumin in the three groups were all lower than those when entering the group, while albumin (ALB), cholinesterase (CHE) and prothrombin (PTA) were all higher than those when entering the three groups, and the biochemical response indexes were compared among the three groups, the differences were statistically significant (all P ＜ 0.05). In addition, ALT and TBil of group C were lower than those of group A and B, while ALB, CHE and PTA were higher than those of group A and B (P ＜ 0.05). After 12 and 24 months of treatment hyaluronic acid (HA), layer mucins (LN), collagen type Ⅳ (ⅣC), collagen type Ⅲ (PCⅢ) of three groups were lower than those when entering the group, and the hepatic fibrosis indexes were compared among the three groups, the differences were statistically significant (P ＜ 0.05), and HA, LN, Ⅳ C, PC Ⅲ of group C were lower than those of group A and B (P ＜ 0.05), after treatment HBeAg/Ab conversion in each group was lower than that before treatment (P ＜ 0.05), and group C was lower than group A and B (P ＜ 0.05). Among the 56 patients who passed the risk period, there was no statistically significant difference in liver histological score between group C and group A, group B before treatment (P ＞ 0.05). The total SSS score of inflammation and liver fibrosis after treatment was lower than that before treatment, and the total SSS score of group C was lower than that of group A and B (P ＜ 0.05). Conclusion The combined treatment of “three antibodies” can significantly improve liver function, liver inflammation, liver fibrosis and inhibition of viral replication, and improve the overall treatment efficiency and quality of life.
2020, Vol. 17 
京公网安备 11010502046598号